BioSpace News Archive

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, chairman and chief executive officer and David Henry, chief financial officer, will present and host one-on-one meetings with investors at the Sidoti Virtual Investor conference being held on June 12-13, 2024.

The Tisch MS Research Center of New York, the world’s largest MS research center, has announced publication of the results of its FDA-approved Phase II stem cell treatment study in a leading stem cell journal, Stem Cell Research & Therapy.

DNA Nanobots, a biotechnology leader in DNA nanoparticles engineered for targeted therapeutics, announced that it completed exclusive commercial licensing of a gene editing technology from the University of California Berkeley.

Vancouver, British Columbia--(Newsfile Corp. - June 5, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announces the results of its Annual General Meeting of Shareholders (“AGM”) held on June 4, 2024.

As the industry witnesses a surge in demand for innovative antibodies on prevalent research targets, Creative Biolabs is poised to meet and exceed these expectations with their comprehensive suite of services.

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today hosted a virtual R&D event focused on the company’s oral small molecule C5aR inhibitor, INF904.

The Department of Health – Abu Dhabi, the regulator of the healthcare sector in the Emirate, signed a Memorandum of Understanding with AstraZeneca during BIO International Convention 2024 to establish a world-class Rare Diseases Centre of Excellence in Abu Dhabi.

Newron Pharmaceuticals S.p.A., a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announced that it will host its 2024 Investor Day on Tuesday, June 25, 2024, in New York City.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced that Pascal Touchon, President and Chief Executive Officer and Cokey Nguyen, Ph.D., Executive Vice President, Chief Scientific & Technical Officer, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024 at 6:20 a.m. PDT / 9:20 a.m. EDT.

AVITA Medical, Inc., a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, announced that the Joseph M. Still Burn Center at Doctors Hospital of Augusta is the first U.S. burn center to treat a patient using its RECELL GO™ System.